Drug induced interstitial lung disease in oncology phase I trials

• DOI: 10.1111/cas.13087
• Publication Date: 2016-09-29T16:42:19Z
• Authors: Kan Yonemori; Akihiro Hirakawa; Asuka Kawachi; Fumie Kinoshita; Hitomi Okuma; Tadaaki Nishikawa; Kenji Tamura; Yasuhiro Fujiwara; Naoko Takebe
• Keywords: Aged, 80 and over; Male; 0301 basic medicine; Clinical Trials, Phase I as Topic; Incidence; Antineoplastic Agents; Original Articles; Middle Aged; Combined Modality Therapy; 3. Good health; 03 medical and health sciences; Risk Factors; Neoplasms; Humans; Female; Lung Diseases, Interstitial; Aged

Interstitial lung disease is a serious drug‐related condition that can cause life threatening organ failure. The incidence and risk factors of drug‐induced interstitial ( DILD ) are unknown in oncology phase I trials. This study analyzed clinical information from 8906 patients with malignancies who were enrolled 470 trials sponsored by the Cancer Therapy Evaluation Program, National Institute, 1988 to 2014. Logistic Cox statistical analyses utilized determine differences between developed did not. In this study, overall rate pulmonary toxicity was 2.7%. for 0.77%, whereas grade 3 or 4 it 0.31%. Median time occurrence 1.4 months. hazard analysis indicated smaller body surface area combination thoracic radiation investigational drug regimens significant disease. Investigators should carefully monitor identified factors. A 6‐month observation period would be sufficient detect onset most such patients.